Compare AstraZeneca plc (AZN) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? AstraZeneca plc trades at $168.5 (market cap $253.13B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.25. The key difference: AstraZeneca plc pays a 1.92% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| AZN | MSTZ | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $27.92 |
52-Week Low | $137.44 | $3.12 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
MSTZ trades at $13.16, up 5.07% today with a bullish technical signal from moving averages. The stock shows neutral oscillators but strong momentum indicators. Key support sits at $13 with resistance at $14. Recent ETF performance news highlights momentum strategies but lacks direct MSTZ coverage.
Outlook hinges on undisclosed fundamentals; current technical strength suggests near-term upside if $14 resistance breaks. Risks include absence of visible financial metrics and reliance on broader market trends. Investors need earnings clarity for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
